<DOC>
	<DOCNO>NCT01167231</DOCNO>
	<brief_summary>The use acarbose impair glucose tolerance ( IGT ) type 2 diabetic subject associate significant reduction cardiovascular event . Additionally , acarbose show beneficial influence cardiovascular risk factor ( metabolic syndrome component ) . Thus , prevention postprandial hyperglycemia acarbose may promise therapeutic strategy reduce increase risk cardiovascular disease . Further study need confirm influence acarbose cardiovascular risk factor real life setting .</brief_summary>
	<brief_title>Prevention Postprandial Hyperglycemia Acarbose May Promising Therapeutic Strategy Reducing Increased Risk Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Diabetes Mellitus Age &gt; /= 18 year Naive acarbose ( minimum 3 month inclusion ) Hypersensitivity acarbose excipients Age &lt; 18 year Pregnancy nurse Inflammatory bowel disease , colonic ulceration , partial intestinal obstruction patient predispose intestinal obstruction Chronic intestinal disease associate mark disorder digestion absorption States may deteriorate result increase gas formation intestine , ( e.g . Roemheld 's syndrome [ angina pectorislike syndrome aggravation angina pectoris due postprandial fill stomach ] large hernia ) Hepatic severe renal impairment ( creatinine clearance &lt; 25 mL/min/ 1,73m2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Acarbose</keyword>
</DOC>